NCT01394445

Pilot Study of Physostigmine-Enhanced Opioid Analgesia

Influence of Physostigmine on Patient-Controlled Analgesia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesize that the administration of physostigmine in the postoperative period after nephrectomy reduces opioid consumption.

Conditions

• Postoperative Pain

Interventions

Type	Name	Description
DRUG	Physostigmine	continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
DRUG	Placebo	continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg

Timeline

• Start date: 2011-06-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-07-14
• Last updated: 2012-02-22

Locations

1 site across 1 country: Austria